Baidu
map

npj Precision Oncology:神奇!小蜜蜂的毒液有大用处,体外实验中可100%杀死癌细胞

2020-09-04 探索菌 生物探索

蜂毒是蜜蜂和马蜂等蜂类毒腺分泌的有毒液体,其主要成分是由26个氨基酸残基组成的蜂毒肽,这是目前人类所知抗炎性最强的物质之一,在抑菌、抗辐射、抗病毒等方面具有显着疗效。

蜂毒是蜜蜂和马蜂等蜂类毒腺分泌的有毒液体,其主要成分是由26个氨基酸残基组成的蜂毒肽,这是目前人类所知抗炎性最强的物质之一,在抑菌、抗辐射、抗病毒等方面具有显着疗效。最近,《npj Precision Oncology》发布的一篇文章通过揭示蜜蜂毒液的生物分子组分作为抗癌药物的分子机制和选择性,为其用于癌症治疗奠定了基础。

具体来说,西澳大利亚大学医学研究中心的研究人员测试了312只蜜蜂和大黄蜂毒液在乳腺癌方面的抗癌特性,发现蜂毒肽能够在60分钟内完全破坏癌细胞膜,并且特定浓度的蜜蜂毒液可以诱导100%的癌细胞死亡,而对正常细胞的影响却很小。

早在1950年,《Nature》杂志就发表了有关蜂毒作用的第一批报告,其中蜂毒减少了植物中肿瘤的生长。然而直到最近这二十年来,人们才对蜜蜂毒液在不同癌症方面的作用产生了浓厚的兴趣。目前,蜂毒及蜂毒肽已在黑色素瘤、非小细胞肺癌、胶质母瘤细胞、白血病等方面显示出抗肿瘤作用,不过不同的蜂毒和蜂毒肽对乳腺癌亚型的影响尚未得到研究。

在这项试验中,研究人员首先在正常的乳腺癌细胞以及乳腺癌临床亚型的细胞上测试了蜜蜂毒液和蜂毒肽,发现二者均具有显着效果,能够选择性和迅速降低了三阴性乳腺癌细胞和富含人表皮生长因子受体-2(HER2,原癌基因)的乳腺癌细胞的活力,并且对正常细胞几乎没有影响。另外,蜂毒肽是毒液中最突出的生物活性抗癌化合物。不过,与蜜蜂相比,大黄蜂的蜂毒肽浓度相对较低。

为了检查细胞死亡的机制和动力学,研究人员用半抑制浓度(IC50)的蜜蜂毒液或蜂毒肽处理了三阴性乳腺癌细胞18小时和24小时,并通过剪切的caspase3分析来量化凋亡细胞的死亡,发现单独的蜂毒肽比蜜蜂毒液诱导更高的凋亡水平。

蜜蜂毒液和蜂毒肽诱导细胞凋亡和膜破坏

在之后的实验中,研究人员更发现,蜂毒肽可以在60分钟内完全破坏癌细胞膜,在20分钟显着减少癌细胞生长和细胞分裂所必需的化学信息。不过,大黄蜂毒液即使在非常高的浓度下也无法诱导细胞死亡。

蜂毒肽可以在60分钟内完全破坏癌细胞膜

进一步研究中,研究人员发现,蜂毒素通过C端存在的带电序列整合到癌细胞的质膜中,从而诱导质膜重塑和破坏。

该报告的首席作者、西澳大利亚大学医学研究中心的Ciara Duffy博士说:“在蜜蜂毒液的影响下,癌症信号通路很快就被关闭了。蜂毒肽通过抑制三阴性乳腺癌中通常过度表达的受体表皮生长因子受体的激活来调节乳腺癌细胞的信号传导,并且抑制了在富含HER2的乳腺癌中过度表达的HER2的激活。”

另外,这项研究还测试了蜂毒肽是否可以与现有的化疗药物一起使用,发现蜂毒肽可以与小分子化合物或化疗药物(例如多西紫杉醇)一起使用,从而治疗高度侵袭性的乳腺癌。蜂毒肽和多西紫杉醇的组合在减少小鼠肿瘤生长方面非常有效。

未参与这项研究的西澳大利亚州首席科学家教授Peter Klinken教授说:“这是令人难以置信的惊喜发现,蜂毒的主要成分蜂毒肽可以抑制致命的乳腺癌细胞,特别是三阴性乳腺癌的生长。更重要的是,这项研究证明了蜂毒肽如何干扰乳腺癌细胞内的信号通路以减少细胞复制。它提供了另一个绝佳的例子,说明天然化合物可用于治疗人类疾病。”

总之,这项研究为辅助开发与频繁耐药性和不良预后相关的多种癌症的新治疗方式提供了参考。不过,研究人员也指出,在进行人体实验之前,还需要进一步评估蜂毒肽的最佳递送方法以及毒性和最大耐受剂量。

原始出处:

Ciara Duffy, Anabel Sorolla, Edina Wang, et al.Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer.npj Precision Oncology. volume 4, Article number: 24 (2020) .Published: 01 September 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-12-28 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-09 ms美霖

    👍

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-06 yxch36
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-04 金黎明

    抓紧时间进行临床实验

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-04 ms7000000139248197

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-04 147573eam02暂无昵称

    期待

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1865903, encodeId=588d1865903c7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 10:21:18 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993617, encodeId=61f1199361ed1, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Sep 30 02:21:18 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674481, encodeId=0dd716e448154, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Feb 08 08:21:18 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883872, encodeId=a5cf8838e227, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200807/9484c971e5f44f9eaff769f5ce71ddcf/814572c1f5654774a44e07ea1a22187d.jpg, createdBy=63e35409263, createdName=ms美霖, createdTime=Wed Sep 09 13:41:59 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252726, encodeId=bbaf1252e26f2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sun Sep 06 01:21:18 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882792, encodeId=adea882e9284, content=抓紧时间进行临床实验, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5af5325692, createdName=金黎明, createdTime=Fri Sep 04 21:20:12 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882757, encodeId=6706882e5740, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200903/79d0f015e6084e5ca462828ca002414e/27d5d6b264cb4eeebf7092dc1fb8eae8.jpg, createdBy=22155415237, createdName=ms7000000139248197, createdTime=Fri Sep 04 18:54:17 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882703, encodeId=8c55882e03c3, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200904/0d20efa54fee49fba0580eddbd3866c6/3e960aa8346342ec837310996af96e30.jpg, createdBy=ebea5209167, createdName=147573eam02暂无昵称, createdTime=Fri Sep 04 15:30:13 CST 2020, time=2020-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038105, encodeId=eed81038105a1, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Sep 04 13:21:18 CST 2020, time=2020-09-04, status=1, ipAttribution=)]
    2020-09-04 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

吉利德与Jounce达成8亿美元合作,打造创新癌症免疫疗法

日前,吉利德科学宣布与Jounce Therapeutics(JNCE.US)达成合作协议,吉利德将获得Jounce的JTX-1811项目的独家研发许可,并向Jounce支付8500万美元的预付款,并

Cancer Cell:效果更强劲!廖学斌/魏来合作揭示HPK1可成为T细胞免疫疗法的靶点

改善T细胞衰竭和增强效应子功能是改善免疫疗法的有希望的策略。HPK1是癌症免疫疗法的有希望的候选靶标。但是尚未很好地确定HPK1在基于T细胞的免疫疗法中的功能意义以及HPK1抑制T细胞功能的分子机制。

Nature:癌细胞通过争夺蛋氨酸躲过免疫系统追杀,邹伟平教授提出“剥夺蛋氨酸,饿死癌细胞”策略

肿瘤细胞通过高表达蛋氨酸转运蛋白SLC43A2来疯狂消耗蛋氨酸,从而竞争性地使T细胞无法获得蛋氨酸。这项研究确定了肿瘤微环境中蛋氨酸代谢、组蛋白修饰和T细胞免疫之间的机制联系。

Nature:终于知道癌细胞为啥那么“豪横”了,原来是它们更能“抢食”

密歇根大学的一支研究团队指出,一种称为蛋氨酸的氨基酸对T细胞的活力和功能影响最大,由于肿瘤细胞比T细胞更擅长“夺取”这种营养物质,造成T细胞中蛋氨酸含量较低,进而改变了组蛋白的修饰模式。

Nature Genetics:癌症的武器是“进化”?科学家发现癌基因在染色体外DNA中扩增,可促进肿瘤发展

ecDNA的存在将改变驱动癌症的癌基因的表达方式,癌基因和其周围的调控区域摆脱了染色体的束缚,从而促进了肿瘤生长。

Lancet oncol:不同癌症患者感染新冠病毒后的死亡率及影响因素

癌症患者的COVID-19预后较差。但癌症是一种异质性的疾病,包括一系列的肿瘤亚型。本研究目的是根据英国癌症患者的肿瘤亚型和患者人口特征调查COVID-19的风险。

Baidu
map
Baidu
map
Baidu
map